TACE Combined with Ralox-HAIC (Oxaliplatin Puls Raltitrexed) and System Therapy in Patients with Unresectable Hepatocellular Carcinoma.

IF 3.9 3区医学 Q2 ONCOLOGY

Journal of Hepatocellular Carcinoma Pub Date : 2026-06-18 eCollection Date: 2026-01-01 DOI:10.2147/JHC.S609273

Ruiqing Liu, Guangshao Cao, Lupeng Li, Jianwen Liu, Huicun Cao, Mengyan Xing, Yangbo Feng, Zesheng Li, Boyu Wang

{"title":"TACE Combined with Ralox-HAIC (Oxaliplatin Puls Raltitrexed) and System Therapy in Patients with Unresectable Hepatocellular Carcinoma.","authors":"Ruiqing Liu, Guangshao Cao, Lupeng Li, Jianwen Liu, Huicun Cao, Mengyan Xing, Yangbo Feng, Zesheng Li, Boyu Wang","doi":"10.2147/JHC.S609273","DOIUrl":null,"url":null,"abstract":"Objective: To retrospective analysis the efficacy and safety of Transarterial Chemoembolization (TACE) combined with Hepatic Arterial Infusion Chemotherapy (Ralox-HAIC, Oxaliplatin + Raltitrexed) and systemic therapy in patients with unresectable Hepatocellular Carcinoma (uHCC).Methods: Clinical data of patients with uHCC who received TACE combined with Ralox-HAIC followed by sequential systemic therapy at our hospital between January 2023 and December 2024 were analyzed. The primary endpoint was Objective Response Rate (ORR). Secondary endpoints included Progression-Free Survival (PFS), Overall Survival (OS) and treatment safety.Results: A total of thirty-six patients with complete data were included. Efficacy evaluation showed: Complete Response (CR) in 6 cases (16.67%), Partial Response (PR) in 22 cases (61.11%), Stable Disease (SD) in 5 cases (13.89%), and Progressive Disease (PD) in 2 cases (5.56%). The ORR was 77.78%, and the Disease Control Rate (DCR) was 91.67%. The median PFS was 12.0 months, and the median OS was 19.0months. The one-year and two-year survival rates were 89% and 38%, respectively. No Grade 4 treatment-related adverse events or treatment-related deaths occurred.Conclusion: TACE combined with Ralox-HAIC and systemic therapy demonstrated a high ORR and DCR with manageable safety in uHCC, warranting further prospective studies for validation.","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"13 ","pages":"609273"},"PeriodicalIF":3.9000,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285937/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S609273","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To retrospective analysis the efficacy and safety of Transarterial Chemoembolization (TACE) combined with Hepatic Arterial Infusion Chemotherapy (Ralox-HAIC, Oxaliplatin + Raltitrexed) and systemic therapy in patients with unresectable Hepatocellular Carcinoma (uHCC).

Methods: Clinical data of patients with uHCC who received TACE combined with Ralox-HAIC followed by sequential systemic therapy at our hospital between January 2023 and December 2024 were analyzed. The primary endpoint was Objective Response Rate (ORR). Secondary endpoints included Progression-Free Survival (PFS), Overall Survival (OS) and treatment safety.

Results: A total of thirty-six patients with complete data were included. Efficacy evaluation showed: Complete Response (CR) in 6 cases (16.67%), Partial Response (PR) in 22 cases (61.11%), Stable Disease (SD) in 5 cases (13.89%), and Progressive Disease (PD) in 2 cases (5.56%). The ORR was 77.78%, and the Disease Control Rate (DCR) was 91.67%. The median PFS was 12.0 months, and the median OS was 19.0months. The one-year and two-year survival rates were 89% and 38%, respectively. No Grade 4 treatment-related adverse events or treatment-related deaths occurred.

Conclusion: TACE combined with Ralox-HAIC and systemic therapy demonstrated a high ORR and DCR with manageable safety in uHCC, warranting further prospective studies for validation.

查看原文本刊更多论文

TACE联合Ralox-HAIC（奥沙利铂+ Raltitrexed）和系统治疗不可切除的肝癌患者。

目的：回顾性分析经动脉化疗栓塞（TACE）联合肝动脉输注化疗（Ralox-HAIC、奥沙利铂+雷替曲塞）及全身治疗在不可切除肝癌（uHCC）患者中的疗效和安全性。方法：分析我院2023年1月至2024年12月间接受TACE联合Ralox-HAIC序贯全身治疗的uHCC患者的临床资料。主要终点为客观缓解率（ORR）。次要终点包括无进展生存期（PFS）、总生存期（OS）和治疗安全性。结果：共纳入36例资料完整的患者。疗效评价：完全缓解（CR） 6例（16.67%），部分缓解（PR） 22例（61.11%），病情稳定（SD） 5例（13.89%），病情进展（PD） 2例（5.56%）。ORR为77.78%，疾病控制率为91.67%。中位PFS为12.0个月，中位OS为19.0个月。1年和2年生存率分别为89%和38%。未发生4级治疗相关不良事件或治疗相关死亡。结论：TACE联合Ralox-HAIC和全身治疗在uHCC中显示出较高的ORR和DCR，安全性可控，值得进一步的前瞻性研究验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊